Effects of Atorvastatin Versus Pravastatin on Platelet Inhibition by Clopidogrel
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
Clopidogrel and statins are frequently coadministered in patients with ischemic heart
diseases. Recent reports suggested that clopidogrel's effectiveness in inhibiting adenosine
diphosphate (ADP)-induced platelets aggregation is attenuated by co-administration of certain
statins. The objective of the present study is to define which kind of statins might
interfere with the antiaggregation property of clopidogrel in patients with acute coronary
Syndrome after percutaneous coronary intervention (PCI).
In this prospective randomized study, all patients in test group will receive clopidogrel
plus atorvastatin, and all patients in control group will receive clopidogrel plus
pravastatin. All patients will be followed up for one year. The primary endpoints include
death, non fatal AMI, urgent revascularization. The secondary endpoints include hemorrhage
events and subacute thrombosis events at 1 year.